Jaguar Animal Health, Inc. (NASDAQ:JAGX) Short Interest Down 82.1% in April

Jaguar Animal Health, Inc. (NASDAQ:JAGX) saw a large drop in short interest during the month of April. As of April 30th, there was short interest totaling 107,543 shares, a drop of 82.1% from the April 15th total of 599,897 shares. Currently, 29.5% of the company’s shares are sold short. Based on an average daily volume of 19,736 shares, the days-to-cover ratio is currently 5.4 days.

Jaguar Animal Health Stock Up 2.5%

Shares of NASDAQ:JAGX traded up $0.08 during midday trading on Wednesday, hitting $3.33. 27,142 shares of the company’s stock traded hands, compared to its average volume of 92,541. The company has a debt-to-equity ratio of 4.08, a quick ratio of 0.29 and a current ratio of 0.50. The company has a market cap of $1.23 million, a PE ratio of 0.00 and a beta of 0.01. The firm’s fifty day moving average price is $13.11 and its two-hundred day moving average price is $30.15. Jaguar Animal Health has a twelve month low of $2.53 and a twelve month high of $241.50.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on JAGX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Tuesday, April 21st. Wall Street Zen upgraded shares of Jaguar Animal Health from a “strong sell” rating to a “sell” rating in a report on Sunday. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Jaguar Animal Health currently has an average rating of “Hold” and a consensus target price of $2,100.00.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.